• Users Online: 839
  • Print this page
  • Email this page
Year : 2021  |  Volume : 4  |  Issue : 2  |  Page : 238-243

Impact of sex of the patient on efficacy and safety of cancer immunotherapy: A retrospective audit

1 Department of Medical Oncology, Mahamana Pandit Madan Mohan Malviya Cancer Center & Homi Bhabha Cancer Hospital, Tata Memorial Center, Varanasi, Uttar Pradesh, India
2 Department of Medical Oncology, Homi Bhabha National Institute, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
3 Department of Radiodiagnosis, Homi Bhabha National Institute, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India

Correspondence Address:
Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Dr. E. Borges Road, Parel East, Mumbai - 400 012, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/crst.crst_111_21

Get Permissions

Background: It has been established that women usually mount a stronger immune response than men of the same age. Data for the efficacy of immune checkpoint inhibitors (ICIs) based on the patient's' sex are scarce. Objectives: We aimed to evaluate the impact of the patients' sex on the efficacy and toxicity of ICIs. Materials and Methods: Aretrospective audit of a prospectively collected database of patients receiving ICIs for advanced solid tumors between August 2015 and November 2018 was performed at the Tata Memorial Hospital in Mumbai, India. The categorical and continuous variables were evaluated using descriptive statistics. The Kaplan–Meier estimator was used to analyze the progression-free survival (PFS) and overall survival (OS). Results: Atotal of 155 patients were included in the study, of which 36 (23.2%) were female and 119 (76.8%) were male. The median PFS was 2.8 months (95% confidence interval [CI], 1.4–4.2) for the male patients and 1.9 months (95% CI, 1.0–2.8) for the female patients (hazard ratio [HR], 1.06; 95% CI, 0.69–1.66; P = 0.764). The median OS was 5.9 months (95% CI, 1.5–10.2) for the male patients and 4.2 months (95% CI, 1.1–7.3) for the female patients (HR, 1.27; 95% CI, 0.77–2.12; P = 0.342). The rates of all toxicities, except for pneumonitis, were similar between the male and female patients. All-grade pneumonitis occurred in a total of 7 (5.8%) male patients, while it was not reported in any female patients. All-grade immune-related adverse effects occurred in 24 (20.2%) male and 4 (18.1%) female patients (P = 0.216). Conclusions: This study shows that the efficacy and toxicity of ICIs are similar in the male and female patients. However, future trials with a balanced number of male and female patients are required to ensure an unbiased estimation of the efficacy and safety of ICIs.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded14    
    Comments [Add]    

Recommend this journal